Join Vistin Pharma ASA's Q3 2024 Conference Call
Vistin Pharma ASA, a prominent player in the pharmaceutical landscape, is gearing up to share its performance metrics for the third quarter of 2024. Scheduled for October 31, 2024, this event marks an essential touchpoint for shareholders and interested stakeholders looking to understand the company’s financial health and strategy moving forward.
Details of the Conference Call
The conference call is set to commence at 08:30 CET on the 31st of October. During this call, management will present the company's operational insights and results for the quarter, followed by an engaging Q&A session. This format allows participants to not only hear the results but also to ask pressing questions directly to the leadership team. The event will be conducted in English.
Accessing the Conference Call
Vistin Pharma ASA has made it easy for stakeholders to join the call. You can participate through different access points, ensuring you have multiple options to stay connected:
Webcast Details
Participants can access the webcast via the following link: https://edge.media-server.com/mmc/p/vbrzzjjk. This platform will provide a comprehensive view of the presentation alongside audio.
Telephone Conference Registration
If you prefer to join via a telephone call, online registration is available at: https://register.vevent.com/register/BI809b345192f14b6882c8bda7de2220b6. This option ensures that participants can easily connect without technical difficulties.
Contact Information for Inquiries
For additional inquiries regarding the conference call or company operations, please contact:
ALEXANDER KARLSEN
CFO
+47 97053621
alexander.karlsen@vistin.com
About Vistin Pharma ASA
Vistin Pharma ASA is a distinguished Norwegian pharmaceutical company recognized for its production of Metformin Hydrochloride (API). The company produces Metformin in various forms, including Direct Compressible lubricated granules. As a dedicated European Metformin supplier, Vistin Pharma is strategically positioned to support leading pharmaceutical companies in meeting their needs. With its headquarters in Oslo and a specialized manufacturing facility in Kragerø, Vistin Pharma is equipped with highly skilled personnel committed to excellence in the pharmaceutical sector.
Market Position and Future Prospects
The pharmaceutical industry is known for its rigor and constant evolution, and Vistin Pharma ASA is no exception. The company’s steadfast commitment to quality and compliance places it in a favorable position as markets continue to expand. Stakeholders can look forward to insights during the Q3 call, which will likely illustrate Vistin's growth trajectory and operational advancements.
Frequently Asked Questions
What are the main results expected to be discussed in the call?
The call will cover Vistin Pharma ASA's performance metrics, including revenue and operational highlights for the third quarter of 2024.
How can I access the conference call?
You can join the call via the provided webcast link or by registering for the telephone conference.
Is there an opportunity for Q&A during the conference call?
Yes, there will be a Q&A session following the management discussion, allowing participants to ask specific questions.
Who can I contact for more information about Vistin Pharma?
For further inquiries, you can reach out to Alexander Karlsen, CFO, at the provided contact details.
What is Vistin Pharma's primary product?
Vistin Pharma ASA specializes in the production of Metformin Hydrochloride, used primarily for treating diabetes.
